CAS 32476-67-8: (3alpha,5beta,8xi,9xi)-3-[(2,6-dideoxy-3-O-methyl-beta-D-glycero-hexopyranosyl)oxy]-5,14-dihydroxycard-20(22)-enolide

Periplocymarin

Periplocymarin is a cardiac glycoside with anticancer potential isolated from Periploca sepium and Periploca graeca.

Periplocymarin is a cardiac glycoside, which is primarily sourced from the plant genus Periploca. This compound functions by inhibiting the Na⁺/K⁺-ATPase pump, leading to an increase in intracellular sodium. This sodium buildup consequently results in enhanced calcium ion concentrations through the sodium-calcium exchanger, thereby strengthening myocardial contractions. In scientific and medical settings, Periplocymarin is particularly valuable for investigating cardiac muscle physiology and potential therapeutic applications. Its ability to increase cardiac contractility makes it a focal point in studies related to heart failure management and other cardiac disorders. Moreover, its mechanism offers insights into cellular ion regulation and the development of treatments for conditions that benefit from increased cardiac output. While its primary applications are in research, the implications of its effects have broad potential in therapeutic innovation.

Periplocymarin, a cardiac glycoside, has potential anti-cancer activity. Octreotide-conjugated periplocymarin demonstrates tumor selectivity and may be useful as a targeting agent to improve the safety profile of cardiac glycosides for cancer therapy.